
‘Give me one week’s time’: Bharat Biotech chief on questions about Covaxin efficacy
Amid concerns over the relatively less amount of data on the efficacy and safety of Covaxin, developed by the Hyderabad-based Bharat Biotech, the company’s managing director Krishna Ella said on Monday that the company’s vaccine is safe and the company is conducting trials in more than 12 countries apart from India. “We are not a company without experience in vaccines. We have tremendous experience in vaccines,” ANI quoted Ella as saying.
“We are touching 123 countries. We are the only company that has got such extensive experience & extensive publication in review journals,” he also said.
“We are not just conducting clinical trials in India. We have done clinical trials more than 12 countries including the UK. We are doing clinical trials in Pakistan, Nepal, Bangladesh & other countries. We are not just an Indian company, we are truly a global company,” Ella also said.
Asked if the vaccine will be effective on new strain of the virus, Ella said, “Give me one week’s time, I will give you confirmed data.”
The government recently approved emergency authorisation use of Oxford-AstraZeneca’s Covishield. The government has also cleared Bharat Biotech International Limited’s locally-developed vaccine for “restricted use in emergency situation” triggering a debate among experts over the approval despite the shorter duration of human trials and relatively less data.
Meanwhile, Indian Council of Medical Research (ICMR) Director General Dr Balram Bhargava had said on Sunday that Covaxin is based on an inactivated whole virus, having potential to target mutated coronavirus strains including the UK variant, and it was a major reason for giving it a conditional nod.
Speaking on the controversy around the vaccine, Ella said, “Now that vaccine is being politicised, I want to state very clearly that none of my family members are associated with any political party.”
“Approval of Covaxin for emergency use is a giant leap for innovation and novel product development in India. It is a proud moment for the nation and a great milestone in India’s scientific capability, a kickstart to the innovation ecosystem in India,” Ella also said.

News updates from HT: Suvendu Adhikari's new challenge ahead of Bengal elections

TRP scam: Mumbai court rejects bail plea of ex-BARC CEO

Vaccine Maitri: India dispatches Covishield to Bhutan, Maldives

‘Like winning Olympic gold’: Kamala Harris' village gears up for her oath taking

Farm laws: SC irked over criticism of court-appointed committee members

TMC MP asks PM Modi to publish controversial book on Netaji, IMA

Avian flu: 1,795 complaints of bird deaths in Mumbai, says BMC

4 soldiers injured in Pakistani firing along LoC in J-K's Akhnoor sector

Speeding BMW kills 2 cops in Chennai, driver held
- Raveendran, who was riding the bike, died on the spot while Karthik, the pillion rider, succumbed to his injuries at a government hospital around 11am, police said.

India Innovation Index ranking out, Karnataka retains top spot

Pakistan names general envoy to Saudi Arabia as military seeks control of ties

Bird flu in Chhattisgarh: 45 wild mynas die in Bijapur, samples to be tested
- The carcasses of the birds were found on Monday and Tuesday near a CRPF camp in Naimad area in the Bijapur district of Chhattisgarh.

Sena questions Centre over reports of China building village in Arunachal

Thulasenthirapuram, Kamala Harris native village in TN, prepares for celebration
